Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Greenstone Appoints Second GreenShield Distributor
18 minutes ago - Market Wire
Related Companies
Symbol Last %Chg
GSHN 0.0013 85.71%
As of 1:39 PM ET 4/21/08
Greenstone Holdings, Inc. (PINKSHEETS: GSHN) announced today that the Company appointed ECO Solutions Inc. a distributor for the GreenShield(TM) product line. Greenstone will supply Greenstone's protective chemical product, GreenShield(TM) to ECO Solutions on a non-exclusive basis for distribution to dealers and large end-users. ECO Solutions Inc. is an affiliate of ECORail Products Inc., the company who has an exclusive agreement for GreenShield process to be used on railroad wood products such as crossties, bridge members and railcar flooring and decking. ECO Solution's territory covers the states of Illinois, Indiana, Iowa, Kentucky, Michigan, Missouri, New York, Ohio, Pennsylvania, Virginia and Wisconsin.
ECO Solutions President & CEO B. Allen Brown stated, "We are extremely excited about the GreenShield product line and look forward to introducing it into the territories assigned by Greenstone. We have already experienced a high level of interest from the potential users we have already contacted."
About Greenstone Holdings, Inc.
(www.egreenstone.com) Greenstone(R) is in the business of providing a variety of unique chemical technologies that are primarily used in the building and construction industry. The Company's first brand name product, GreenShield(TM), offers a "green" solution to protect wood-based building materials such as lumber, logs, plywood, drywall, railroad ties, fencing, and utility poles from destructive environmental elements. It also offers added fire retardancy to the material it is applied to. The $25 billion water damage market is just one example of the perfect niche for GreenShield. Greenstone also exclusively distributes Green-Dri(TM), a revolutionary biological dry kiln for drying wood, Permeate(TM), a very unique anti-corrosion sealer paint for metal, concrete, and other construction materials, MagneLine(R), a very strong polymer cement mortar used to reinforce and/or repair metal and concrete structures such as bridges and highways, and Crystal-Guard(TM), an innovative chemical to make asbestos harmless and recyclable.
Forward-Looking Statements:
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors effecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission.
CONTACT:
Dominic Martinez
M&M Investor Relations
Toll Free 866-508-2092
Email Contact
For those who've just boardmarked:
Greenstone Introduces Fire-Pruf(TM) Wood, Non-Flammable Wood for Homes and Buildings
Wednesday 04/16/2008 8:31 AM ET - Market Wire
Related Companies
Symbol Last %Chg
GSHN 0.0013 85.71%
As of 12:11 PM ET 4/21/08
Greenstone Holdings, Inc. (PINKSHEETS: GSHN) announced today that the Company has introduced a new product, Fire-Pruf(TM) a special chemical to treat wood and make it completely fire-proof. Fire-Pruf(TM) has been invented by Mr. Toshio Ito of Nippon Funen Mokuzai(NFM) in Japan. NFM is also the manufacturer of Green-Dri(TM) Biological Dry Kiln. Fire-Pruf treated wood has recently been officially accepted by the Japanese Imperial Household Agency, a management agency overseeing the properties of Japanese Imperial families, many of which are wooden structures. The first delivery of Fire-Pruf treated cypress material was just made in late March.
"We are very excited about the introduction of Fire-Pruf especially for home owners in California," said Sal Miwa, CEO of Greenstone.
About Greenstone Holdings, Inc.
Greenstone(R) (www.egreenstone.com) is in the business of providing a variety of unique chemical technologies that are primarily used in the building and construction industry. The Company's first brand name product, GreenShield(TM), offers a "green" solution to protect wood-based building materials such as lumber, logs, plywood, drywall, railroad ties, fencing, and utility poles from destructive environmental elements. It also offers added fire retardancy to the material it is applied to. The $25 billion water damage market is just one example of the perfect niche for GreenShield. Greenstone also exclusively distributes Green-Dri(TM), a revolutionary biological dry kiln for drying wood, Permeate(TM), a very unique anti-corrosion sealer paint for metal, concrete, and other construction materials, MagneLine(R), a very strong polymer cement mortar used to reinforce and/or repair metal and concrete structures such as bridges and highways, and Crystal-Guard(TM), an innovative chemical to make asbestos harmless and recyclable.
Forward-Looking Statements:
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors effecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission.
Welcome to the board :)
Nevermind, there we are on the active list :) #20 with 68 posts
GSHN HOD
Why are we not on the most active forums list?
Good job to all who were in HFBV, should take another leg up after the CEO actually starts.
GSHN back to HOD
Not getting filled on the ASK.
How did Hansen's finance themselves after Rosario took over? I will look, but does anyone know?
Outstanding Shares
729,360,121 as of Feb 26, 2008
Authorized Shares
750,000,000 as of Jan 18, 2008
Number of Share Holders of Record
567 as of Oct 17, 2007
Float
306,000,014 as of Feb 15, 2008
Any thoughts on the OS being so close to the AS?
What would an optimist and a pessimist each say about the O/S being so close to the A/S?
Were you wondering who the Pink Lawyer is?
http://investorshub.advfn.com/boards/board.asp?board_id=7516
Purio Inc. Rated 'Speculative Buy,' Target Price $1.10 by Beacon Equity Research
0 minutes ago - Businesswire
Related Companies
Symbol Last %Chg
PURO 0.45 0.00%
As of 12:00 AM ET 4/18/08
Purio Inc. (OTCBB: PURO) has been rated Speculative Buy with a price target of $1.10 by Beacon Equity Research Analyst, Victor Sula, Ph.D.
The full report is available at http://www.BeaconEquity.com.
Anyone interested in receiving alerts regarding Purio Inc. research should e-mail members@beaconequity.com with "PURO" in the subject line.
In the report, the analyst writes, "Purio Inc. (PURO) is a development-stage company involved in the design, manufacture and commercialization of water treatment systems and products. The Company's patented continuous-flow water/suspended-solids separation technology has applications in wastewater treatment, water re-cycling and drinking water production. PURO's technology has been tested by an independent laboratory, Canadian Environmental Technology Advancement Corporation-West (CETAC-WEST), and deemed effective in meeting enhanced primary treatment standards for BOD (biological oxygen demand) and TSS (total suspended solids). In addition, the technology exceeded standards for phosphorus removal."
Other companies in the water treatment sector include Aqua America (NYSE: WTR), Basin Water (Nasdaq: BWTR), Pall Corp. (NYSE: PLL), and York Water (Nasdaq: YORW).
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of Purio Inc. Additionally the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. BER and its affiliates have been compensated a total of seven thousand five hundred dollars from Pine Mountain Ventures for enrollment of PURO in its research program and other services. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
SOURCE: Purio Inc.
BeaconEquity.com
Jeff Bishop, 469-252-3505
press@beaconequity.com
www.BeaconEquity.com
or
Purio Inc.
Shawn Van Damme, 877-512-1120
GM - They might have to :)
we'll close green today, IMO... load up while you can.
Any speculation about which (if any) HGTV show they'll try to target for Clean1? Curb Appeal, maybe?
Great PR... could it be the first of two today?
CLEAN1(TM) Outdoor Cleaner Deliveries Begin to Home Hardware Stores
7 minutes ago - Market Wire
Related Companies
Symbol Last %Chg
WNBD 0.0228 0.00%
As of 12:00 AM ET 4/17/08
Winning Brands Corporation (PINKSHEETS: WNBD) (FRANKFURT: WMU) (www.WinningBrands.ca) reports that its CLEAN1(TM) brand of outdoor cleaner was available for the first time for orders from Home Hardware associate stores at the group's Spring Market, April 13-15th. Home Hardware is a group of approximately 1,000 associated retailers located coast-to-coast and is a member of Alliance International LLC, the third-largest hardware and building materials partnership in North America. It had been announced earlier that CLEAN1(TM) had gained permission to begin sales through Home Hardware stores and that the Spring Market would be the formal launch point. The orders now taken at the show by participating dealers follow the first orders placed for CLEAN1(TM) in North America at an earlier reported Val-Test show in Naples, Florida.
With recent progress in developing the basic jingle elements for the new brand, and firm orders now in hand from a broad range of participating Home Hardware stores, Winning Brands will complete the radio and television commercial associated with this brand and commence the company's 2nd broadcast initiative.
There is currently no dominant category leader for "outdoor" cleaners -- a category that CLEAN1(TM) has been specifically designed to fill. Power washers, boats, bikes, BBQs, siding and swimming pools are only some of the popular lifestyle and industrial applications for the advanced cleaning solution. As the retailer partnerships of Winning Brands grow in number, this broadening of the company's advertised product base helps to provide continuing momentum for growth within these partnerships, representing business that is in addition to Winning Colours(R) Stain Remover -- the company's first high profile consumer product.
Winning Brands CEO Eric Lehner remains conservative in his characterization of this development and its implications. "We are doing what we said we would do -- and that is one of the corner stones of developing an enterprise of any value. Projections, possibilities and potential are all meaningless unless there is the follow-through. Now that we have CLEAN1(TM) going into a sufficient number of retailers to justify advertising initiatives, we are going to do what people have come to expect of us -- keep building! What matters more than situations on any single day is the pattern. Does the company invest its resources into developing momentum that will gain a life of its own -- that's the thing to look for. Also, the more solid we are in our home market of North America, the more likely we are to arrange distribution abroad. CLEAN1(TM) is now emerging and can begin to do for us in 2009 what Winning Colours(R) Stain Remover is already starting to do now."
Winning Brands will announce the broadcast schedule for CLEAN1(TM) on TV as soon as the production of the TV commercial is finished.
Certain statements in this news release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Winning Brands Corporation (the Company) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; and (iii) competitive factors and developments beyond the Company's control. Winning Colors(R), Winning Colours(R), KIND(TM) and CLEAN1(TM) are trademarks of Niagara Mist Marketing Ltd. SMART(TM) Wet Cleaning Solutions is a trademark of Solvent Free Solutions Inc.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=74068
CLEAN1(TM) Outdoor Cleaner Deliveries Begin to Home Hardware Stores
7 minutes ago - Market Wire
Related Companies
Symbol Last %Chg
WNBD 0.0228 0.00%
As of 12:00 AM ET 4/17/08
Winning Brands Corporation (PINKSHEETS: WNBD) (FRANKFURT: WMU) (www.WinningBrands.ca) reports that its CLEAN1(TM) brand of outdoor cleaner was available for the first time for orders from Home Hardware associate stores at the group's Spring Market, April 13-15th. Home Hardware is a group of approximately 1,000 associated retailers located coast-to-coast and is a member of Alliance International LLC, the third-largest hardware and building materials partnership in North America. It had been announced earlier that CLEAN1(TM) had gained permission to begin sales through Home Hardware stores and that the Spring Market would be the formal launch point. The orders now taken at the show by participating dealers follow the first orders placed for CLEAN1(TM) in North America at an earlier reported Val-Test show in Naples, Florida.
With recent progress in developing the basic jingle elements for the new brand, and firm orders now in hand from a broad range of participating Home Hardware stores, Winning Brands will complete the radio and television commercial associated with this brand and commence the company's 2nd broadcast initiative.
There is currently no dominant category leader for "outdoor" cleaners -- a category that CLEAN1(TM) has been specifically designed to fill. Power washers, boats, bikes, BBQs, siding and swimming pools are only some of the popular lifestyle and industrial applications for the advanced cleaning solution. As the retailer partnerships of Winning Brands grow in number, this broadening of the company's advertised product base helps to provide continuing momentum for growth within these partnerships, representing business that is in addition to Winning Colours(R) Stain Remover -- the company's first high profile consumer product.
Winning Brands CEO Eric Lehner remains conservative in his characterization of this development and its implications. "We are doing what we said we would do -- and that is one of the corner stones of developing an enterprise of any value. Projections, possibilities and potential are all meaningless unless there is the follow-through. Now that we have CLEAN1(TM) going into a sufficient number of retailers to justify advertising initiatives, we are going to do what people have come to expect of us -- keep building! What matters more than situations on any single day is the pattern. Does the company invest its resources into developing momentum that will gain a life of its own -- that's the thing to look for. Also, the more solid we are in our home market of North America, the more likely we are to arrange distribution abroad. CLEAN1(TM) is now emerging and can begin to do for us in 2009 what Winning Colours(R) Stain Remover is already starting to do now."
Winning Brands will announce the broadcast schedule for CLEAN1(TM) on TV as soon as the production of the TV commercial is finished.
Certain statements in this news release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Winning Brands Corporation (the Company) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; and (iii) competitive factors and developments beyond the Company's control. Winning Colors(R), Winning Colours(R), KIND(TM) and CLEAN1(TM) are trademarks of Niagara Mist Marketing Ltd. SMART(TM) Wet Cleaning Solutions is a trademark of Solvent Free Solutions Inc.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=74068
Sounds good to me.
Looks like the Rocketship crew has taken over here.. To those of you who've been here all along the board's in good hands now.
I'll be watching for now but good luck to all.
I just wanted to clarify that the claim was in fact made, and very clearly so: "completely non-flammable."
The company's now made a clear distinction between what Greenshield and Fire-pruf do in terms of fire protection; they'll have to back that distinction up somehow.
Obviously "more fire resistant" is not the same as fire proof, but that's not what they said, and as unreal as it sounds the PR is pretty much all we can go on until we see what the follow up PR's or demonstrations say, if there are any. If not, then the warranted skepticism of the investors should - and will - take over.
I won't believe it until I see it for myself either, but I can't imagine any CEO throwing out such a bold claim so loosely without at least hoping it was really true. (although they do seem to have planned on diluting right after that PR was released, so who knows)
The fire-pruf PR DOES say fire proof, not fire resistant. Greenshield is a different product that makes treated wood only fire resistant.
Greenstone Introduces Fire-Pruf(TM) Wood, Non-Flammable Wood for Homes and Buildings
Wednesday 04/16/2008 8:31 AM ET - Market Wire
As of 1:07 PM ET 4/17/08
Greenstone Holdings, Inc. (PINKSHEETS: GSHN) announced today that the Company has introduced a new product, Fire-Pruf(TM) a special chemical to treat wood and make it completely fire-proof. Fire-Pruf(TM) has been invented by Mr. Toshio Ito of Nippon Funen Mokuzai(NFM) in Japan. NFM is also the manufacturer of Green-Dri(TM) Biological Dry Kiln. Fire-Pruf treated wood has recently been officially accepted by the Japanese Imperial Household Agency, a management agency overseeing the properties of Japanese Imperial families, many of which are wooden structures. The first delivery of Fire-Pruf treated cypress material was just made in late March.
"We are very excited about the introduction of Fire-Pruf especially for home owners in California," said Sal Miwa, CEO of Greenstone.
About Greenstone Holdings, Inc.
Greenstone(R) (www.egreenstone.com) is in the business of providing a variety of unique chemical technologies that are primarily used in the building and construction industry. The Company's first brand name product, GreenShield(TM), offers a "green" solution to protect wood-based building materials such as lumber, logs, plywood, drywall, railroad ties, fencing, and utility poles from destructive environmental elements. It also offers added fire retardancy to the material it is applied to. The $25 billion water damage market is just one example of the perfect niche for GreenShield. Greenstone also exclusively distributes Green-Dri(TM), a revolutionary biological dry kiln for drying wood, Permeate(TM), a very unique anti-corrosion sealer paint for metal, concrete, and other construction materials, MagneLine(R), a very strong polymer cement mortar used to reinforce and/or repair metal and concrete structures such as bridges and highways, and Crystal-Guard(TM), an innovative chemical to make asbestos harmless and recyclable.
Forward-Looking Statements:
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors effecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission.
CONTACT:
Dominic Martinez
M&M Investor Relations
Toll Free 866-508-2092
Email Contact
BioForce Nanosciences Reports Doubling of Quarterly and Annual Revenue, Gross Profit
March 31, 2008
BIOFORCE NANOSCIENCES REPORTS DOUBLING OF QUARTERLY AND ANNUAL REVENUE, GROSS PROFIT
Sales of Nano eNabler™ Rise Sharply in 2007
Sales Momentum Continues with Five Nano eNabler™ System Sales in Q1 2008
AMES, IA, March 31, 2008 -- BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micro and nano scales, today announced record revenue and gross profit for the fourth quarter and full year ended December 31, 2007.
Fourth Quarter Highlights
·Net revenues were a record $545,622 for the fourth quarter of 2007, a 256% increase from net revenues of $153,459 for the fourth quarter of 2007.
·Gross profit was a record $378,356 for the fourth quarter of 2007, a 581% increase from gross profit of $55,584 for the fourth quarter of 2006.
·Net loss on common stock was $597,669 ($0.02 per fully diluted share) for the fourth quarter of 2007, as compared to a net loss on common stock of $1,163,259 ($0.05 per fully diluted share) for the fourth quarter of 2006.
2007 Highlights
·Net revenues were a record $1,125,030 for the year ended December 31, 2007, a 171% increase from net revenues of $415,087 for the year ended December 31, 2006.
·Gross profit was a record $523,846 for the year ended December 31, 2007, a 143% increase from gross profit of $215,938 for the year ended December 31, 2006.
·Net loss on common stock was $4,009,833 ($0.17 per fully diluted share) for the year ended December 31, 2007, as compared to a net loss on common stock of $3.974,083 ($0.17 per fully diluted share) for the year ended December 31, 2006.
Operations Review
Kerry Frey, President and Chief Executive Officer of BioForce, said, “This was a good year and a great quarter for BioForce. We sold nine Nano eNabler™ systems during 2007, as compared to two Nano eNabler™ systems during 2006. Of those nine sales during 2007, five occurred during the fourth quarter of the year. For the year six of our nine Nano eNabler™ system sales were to overseas customers. Our loss for the fourth quarter of 2007 narrowed dramatically from the results in prior quarters, and we remain focused upon achieving profitability.
“During 2007 we made the transition from a development stage company to a commercial enterprise. We have also proved ourselves capable of operating as a global company. International sales represent a significant portion of our business, with our distributors doing a great job of helping us penetrate the market in Europe and Asia.”
Frey continued, “We continued to develop our intellectual property portfolio in 2007. Just touching on the highlights, we received notice from the U.S. Patent and Trademark Office (USPTO) that our ``Protein Nanoarray'' patent had been upheld, a Notice of Allowance from the USPTO for our Sindex™ chips, and a Notice of Allowance from the USPTO for our Chip-On-A-Tip™ patent.
“In 2007 we saw the Nano eNabler™ system adopted by customers for a variety of research activities, with two key areas being cell biology and biosensor development. The Nano eNabler’s ability to deposit miniscule quantities of biological materials with extremely high precision and flexibility allows for the creation of biological microenvironments necessary to study cellular growth at the single cell level, and development of ultra-miniaturized diagnostic tests and devices. Ultimately, these could lead to breakthrough discoveries in the areas of cancer therapy, stem cell therapy and tissue engineering, as well as development of diagnostic tests with increased sensitivity and requiring far less source material.
Frey concluded, “We anticipate that 2008 will be another good year for us as we introduce new products to the market, and as the effect of our enhanced sales team begins to show in further sales. I am pleased to announce that the sales momentum developed during 2007 has continued into 2008, with an additional five Nano eNabler™ systems having been sold during the three months ended March 31, 2008. Two of these sales were via our overseas distribution network, and three were to premier research institutions in the United States. While we are enthused about this result, and believe that it does demonstrate the groundswell of demand for the Nano eNabler™, we remind investors that our progress is best viewed over a longer time frame than by comparing consecutive quarters.”
VIEW CONSOLIDATED STATEMENT OF OPERATIONS AS PDF
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences creates products and solutions for the life sciences by integrating biological and mechanical systems at the micro and nano scales. BioForce’s flagship product, the Nano eNabler™ molecular printer, gives the Company and its customers a platform for development and discovery by printing tiny domains of biological materials on surfaces with nanometer spatial precision. BioForce technology is being used in areas such as biosensor functionalization; pattering and cell adhesion; and the printing of proteins to guide neural cell growth. For more information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
News Archive
What's their story? website?
Agreed.. has anyone called the TA today?
Greenstone's Green Chemical, GreenShield(TM), Was Featured in Building Products Magazine
Thursday 04/17/2008 8:30 AM ET - Market Wire
As of 10:56 AM ET 4/17/08
Greenstone Holdings, Inc. (PINKSHEETS: GSHN) announced today that the Company's flagship product, GreenShield(TM), was listed in one of the new product announcements in this month's Building Products Magazine. "Greenstone's GreenShield is formulated to protect building materials such as lumber, plywood, and drywall from water, moisture and fire. The thin, clear liquid reportedly penetrates and encapsulates the material at the molecular level. Totally organic, it quickly crystallizes without changing the material's color and resists UV rays," said the article.
""""""""""""""""""""""""""""""""""""""""
Also, cup and handle forming on BLLB?
Hi Shef, thanks again for the invite to this board. Coincidentally, GSHN has been on my radar for quite some time and I plan on finally taking a substantial position this week. I love the 'green' plays and GSHN seems to be legit.
I go to several conferences a year, I'd be so excited to see Aethlon representatives there or to see references in papers someday...
All that being said, I think they're just being extremely conservative. They haven't had any problem so far, and the applications of their proprietary technology have only gotten better since the 10Q came out. They're just being really cautious about what they say.
NOTE 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
Aethlon Medical, Inc. (the "Company") is a development stage medical device
company focused on expanding the applications of our Hemopurifier (R) platform
technology, which is designed to rapidly reduce the presence of infectious
viruses and other toxins from human blood. In this regard, our core focus is the
development of therapeutic devices that treat acute viral conditions, chronic
viral diseases and pathogens targeted as potential biological warfare agents.
The Hemopurifier(R) combines the established scientific principles of affinity
chromatography and hemodialysis as a means to mimic the immune system's response
of clearing viruses and toxins from the blood before cell and organ infection
can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent
virus and toxins from infecting unaffected tissues and cells. We have completed
pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C,
and have completed human safety trials on Hepatitis-C infected patients in India
and are in the process of obtaining regulatory approval from the U.S. Food and
Drug Administration ("FDA") to initiate clinical trials in the United States.
The commercialization of the Hemopurifier(R) will likely require the completion
of human efficacy clinical trials. The approval of any application of the
Hemopurifier(R) in the United States will necessitate the approval of the FDA to
initiate human studies. Such studies could take years to demonstrate safety and
effectiveness in humans and there is no assurance that the Hemopurifier(R) will
be cleared by the FDA as a device we can market to the medical community. We
also expect to face similar regulatory challenges from foreign regulatory
agencies, should we attempt to commercialize and market the Hemopurifier(R)
outside of the United States. As a result, we have not generated revenues from
the sale of any Hemopurifier(R) application. Additionally, there have been no
independent validation studies of our Hemopurifiers(R) to treat infectious
disease. We manufacture our products on a small scale for testing purposes but have yet to manufacture our products on a large scale for commercial purposes.
All of our pre-clinical human blood studies have been conducted in our
laboratories under the direction of Dr. Richard Tullis, our Chief Science
Officer.
The Company is classified as a development stage enterprise under accounting
principles generally accepted in the United States of America ("GAAP"), and has
not generated revenues from its principal operations.
The Company's common stock is quoted on the Over-the-Counter Bulletin Board of
the National Association of Securities Dealers under the symbol "AEMD.OB".
The accompanying unaudited condensed consolidated financial statements of the
Company have been prepared in accordance with GAAP for interim financial
information. Accordingly, they do not include all of the information and
footnotes required by GAAP for complete financial statements. In the opinion of
management, all adjustments (consisting of normal recurring adjustments)
considered necessary for a fair presentation have been included. Operating
results for the three and nine month periods ended December 31, 2007 are not
necessarily indicative of the results that may be expected for the year ending
March 31, 2008. For further information, refer to the Company's Annual Report On
Form 10-KSB for the year ended March 31, 2007, which includes audited financial
statements and footnotes as of March 31, 2007 and for the years ended March 31,
2006 and 2007.
6
NOTE 2. GOING CONCERN AND LIQUIDITY CONSIDERATIONS
The accompanying unaudited condensed consolidated financial statements have been
prepared on a going concern basis, which contemplates, among other things, the
realization of assets and the satisfaction of liabilities in the ordinary course
of business. The Company has experienced continuing losses from operations, is
in default on certain debt, has negative working capital of approximately
($3,676,000) recurring losses from operations and a deficit accumulated during
the development stage of approximately ($31,481,000) at December 31, 2007, which
among other matters, raises significant doubt about its ability to continue as a
going concern. The Company has not generated significant revenue or any profit
from operations since inception. A significant amount of additional capital will
be necessary to advance the development of the Company's products to the point
at which they may become commercially viable. The Company intends to fund
operations through debt and/or equity financing arrangements, which management
believes may be insufficient to fund its capital expenditures, working capital
and other cash requirements (consisting of accounts payable, accrued
liabilities, amounts due to related parties and amounts due under various notes
payable) for the fiscal year ending March 31, 2008. Therefore the Company will
be required to seek additional funds to finance its short-term operations.
The Company is currently addressing its liquidity issue by exploring investment
capital opportunities through the public markets, specifically, through private
placement of common stock. The Company believes that its access to capital,
together with existing cash resources, will be sufficient to meet its liquidity
needs for fiscal 2008. However, no assurance can be given that the Company will
receive any funds in addition to the funds in its capital raising efforts.
The unaudited condensed consolidated financial statements do not include any
adjustments relating to the recoverability of assets that might be necessary
should the Company be unable to continue as a going concern.
NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The summary of significant accounting policies of the Company presented below is
designed to assist the reader in understanding the Company's condensed
consolidated financial statements. Such financial statements and related notes
are the representations of Company management, who is responsible for their
integrity and objectivity. These accounting policies conform to GAAP in all
material respects, and have been consistently applied in preparing the
accompanying condensed consolidated financial statements.
PRINCIPLES OF CONSOLIDATION
The accompanying condensed consolidated financial statements include the
accounts of Aethlon Medical, Inc. and its legal wholly-owned subsidiaries
Aethlon, Inc., Hemex, Inc. and Cell Activation, Inc. (collectively hereinafter
referred to as the "Company"). These subsidiaries are dormant and there exist no
material intercompany transactions or balances.
LOSS PER COMMON SHARE
Loss per common share is based on the weighted average number of shares of
common stock and common stock equivalents outstanding during the year in
accordance with SFAS No. 128, "EARNINGS PER SHARE."
Securities that could potentially dilute basic loss per share (prior to their
conversion, exercise or redemption) were not included in the
diluted-loss-per-share computation because their effect is anti-dilutive. There
were 17,531,110 and 14,209,120 potentially dilutive common shares outstanding
for the three and nine months ended December 31, 2007, respectively.
LIQUIDITY AND CAPITAL RESOURCES
To date, the Company has funded its capital requirements for the current
operations from net funds received from the public and private sale of debt and
equity securities, as well as from the issuance of common stock in exchange for
services. The Company's cash position at December 31, 2007 was approximately
$333,000 compared to approximately $440,000, at March 31, 2007, representing a
decrease of approximately $107,000. During the nine months ended December 31,
2007, operating activities used net cash of approximately $1,079,000, while the
Company received approximately $983,000 from financing activities from the
issuance of common stock and convertible notes and utilized approximately
$11,000 in connection with patent costs and purchases of new equipment.
During the nine month period ended December 31, 2007, net cash used in operating
activities were approximately ($1,079,000) and resulted from the approximate net
loss of $3,394,000, the change in the estimated fair value of warrant liability
of approximately $3,958,000 and a reduction of accounts payable and accrued
expenses of approximately $439,000. These were offset principally by the
non-cash loss on debt extinguishment of approximately $491,000, amortization of
note discount of $911,000, fair market value of common stock of approximately
$197,000 issued in payment for services and approximately $422,000 in
stock-based compensation.
An increase in working capital during the nine months ended December 31, 2007 in
the amount of approximately $3,584,000 changed the Company's negative working
capital position to approximately ($3,676,000) at December 31, 2007 from a
negative working capital of approximately ($7,260,000) at March 31, 2007.
The Company's current deficit in working capital required us to obtain funds in
the short-term to be able to continue in business, and in the longer term to
fund research and development on products not yet ready for market.
The Company's operations to date have consumed substantial capital without
generating revenues, and will continue to require substantial capital funds to
conduct necessary research and development and pre-clinical and clinical testing
of Hemopurifier(R) products, and to market any of those products that receive
regulatory approval. The Company does not expect to generate revenue from
operations for the foreseeable future, and its ability to meet its cash
obligations as they become due and payable is expected to depend for at least
the next several years on its ability to sell securities, borrow funds or a
combination thereof. The Company's future capital requirements will depend upon
many factors, including progress with pre-clinical testing and clinical trials,
the number and breadth of our programs, the time and costs involved in
preparing, filing, prosecuting, maintaining and enforcing patent claims and
other proprietary rights, the time and costs involved in obtaining regulatory
approvals, competing technological and market developments, and management's
ability to establish collaborative arrangements, effect successful
commercialization strategies, marketing activities and other arrangements. The
Company expects to continue to incur increasing negative cash flows and net
losses for the foreseeable future, and presently requires a minimum of $125,000
per month to sustain operations.
Management does not believe that inflation has had or is likely to have any
material impact on the Company's limited operations.
At the date of this filing, we do not have plans to purchase significant amounts
of equipment or hire significant numbers of employees prior to successfully
raising additional capital.
19
PLAN OF OPERATION
The Company is a development stage medical device company that has not yet
engaged in significant commercial activities. The primary focus of our resources
is the advancement of our proprietary Hemopurifier(R) platform treatment
technology, which is designed to rapidly reduce the presence of infectious
viruses and toxins in human blood. Our focus is to prepare our Hemopurifier(R)
to treat chronic viral conditions, acute viral conditions and viral-based
bioterror threats in human clinical trials.
The Company plans to continue research and development activities related to our
Hemopurifier(R) platform technology, with particular emphasis on the advancement
of our treatment for "Category A" pathogens as defined by the Federal Government
under Project Bioshield and the All Hazards Preparedness Act of 2006. The
Company has filed an Investigational Device Exemption ("IDE") with the FDA in
order to proceed with Human safety studies of the Hemopurifier(R). Such studies,
complemented by planned in-vivo and appropriate animal in-vitro studies should
allow the Company to proceed to Premarket Approval ("PMA") process. The PMA
process is the last major FDA hurdle in determining the safety and effectiveness
of Class III medical Devices (of which the Hemopurifier(R) is one).
Subject to the availability of working capital, management anticipates
continuing to increase spending on research and development over the next 12
months. Additionally, associated with the Company's anticipated increase in
research and development expenditures, we anticipate purchasing additional
amounts of equipment during this period to support our laboratory and testing
operations. Operations to date have consumed substantial capital without
generating revenues, and will continue to require substantial and increasing
capital funds to conduct necessary research and development and pre-clinical and
clinical testing of our Hemopurifier(R) products, as well as market any of those
products that receive regulatory approval. The Company does not expect to
generate revenue from operations for the foreseeable future, and our ability to
meet our cash obligations as they become due and payable is dependent for at
least the next several years on our ability to sell securities, borrow funds or
a combination thereof. Future capital requirements will depend upon many
factors, including progress with pre-clinical testing and clinical trials, the
number and breadth of our clinical programs, the time and costs involved in
preparing, filing, prosecuting, maintaining and enforcing patent claims and
other proprietary rights, the time and costs involved in obtaining regulatory
approvals, competing technological and market developments, as well as
management's ability to establish collaborative arrangements, effective
commercialization, marketing activities and other arrangements. The Company
expects to continue to incur increasing negative cash flows and net losses for
the foreseeable future.
They don't sound very optimistic in their 10Q. I hope they start commencing sales soon...
Please give them the most recent news, as well...
Symbollon Pharmaceuticals Announces Results of IoGen Phase III Clinical Trial
Thursday 04/10/2008 8:00 AM ET - Market Wire
Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced the results of a Phase III clinical trial designed to evaluate the effectiveness of IoGen(TM) for the treatment of moderate to severe cyclic pain associated with fibrocystic breast disease. In the study, patients were dosed once a day for up to six months with either a 6-mg IoGen tablet or placebo. There was no statistically significant difference between the treatment groups on the primary endpoint of pain reduction. The findings demonstrated equivalence between the active 6-mg IoGen formulation and the placebo in achieving the primary efficacy endpoint. The data also showed no statistically significant difference between the two groups in achieving the secondary efficacy endpoint of fibrosis reduction. The overall incidence rates of treatment-related adverse events, serious adverse events or adverse events leading to discontinuation were generally similar between treatment groups.
The study randomized 142 patients. Of this group, 61 patients were included in the IoGen intent-to-treat group and 65 patients in the placebo intent-to-treat group. IoGen was clinically successful in achieving the primary efficacy endpoint of pain reduction in 34 of 61 (56%) patients, compared to positive responders in the placebo group of 38 of 65 (58%) patients. IoGen was successful in achieving the secondary endpoint of at least 25% reduction of fibrosis in 38 of 54 (71%) patients, compared to positive responders in the placebo group of 39 of 61 (64%) patients.
"We are extremely surprised and disappointed by the high placebo results in this study," said Paul Desjourdy, President and CEO of Symbollon Pharmaceuticals. "While we will continue to evaluate the data, the results of this study will severely limit our ability to proceed with the clinical development of IoGen. Based on the Company's limited resources, management and the Board of Directors will be evaluating the Company's ability to continue operations. We have adequate resources to continue operations through June. In light of these clinical results, it may be difficult for us to raise additional resources. Our focus will be to maximize shareholder value by leveraging the Company's proprietary technology."
Did you guys ever create the "green" board? GSHN is another interesting play. I' just took up a position, take a look:
http://www.egreenstone.com/
GSHN has been on my watchlist for quite some time. I think itll be an interesting play. Thanks for the invite to the board.
Is the L2 suspicious?
Is this symba? Most recent news:
Symbollon Pharmaceuticals Announces Results of IoGen Phase III Clinical Trial
Thursday 04/10/2008 8:00 AM ET - Market Wire
Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced the results of a Phase III clinical trial designed to evaluate the effectiveness of IoGen(TM) for the treatment of moderate to severe cyclic pain associated with fibrocystic breast disease. In the study, patients were dosed once a day for up to six months with either a 6-mg IoGen tablet or placebo. There was no statistically significant difference between the treatment groups on the primary endpoint of pain reduction. The findings demonstrated equivalence between the active 6-mg IoGen formulation and the placebo in achieving the primary efficacy endpoint. The data also showed no statistically significant difference between the two groups in achieving the secondary efficacy endpoint of fibrosis reduction. The overall incidence rates of treatment-related adverse events, serious adverse events or adverse events leading to discontinuation were generally similar between treatment groups.
The study randomized 142 patients. Of this group, 61 patients were included in the IoGen intent-to-treat group and 65 patients in the placebo intent-to-treat group. IoGen was clinically successful in achieving the primary efficacy endpoint of pain reduction in 34 of 61 (56%) patients, compared to positive responders in the placebo group of 38 of 65 (58%) patients. IoGen was successful in achieving the secondary endpoint of at least 25% reduction of fibrosis in 38 of 54 (71%) patients, compared to positive responders in the placebo group of 39 of 61 (64%) patients.
"We are extremely surprised and disappointed by the high placebo results in this study," said Paul Desjourdy, President and CEO of Symbollon Pharmaceuticals. "While we will continue to evaluate the data, the results of this study will severely limit our ability to proceed with the clinical development of IoGen. Based on the Company's limited resources, management and the Board of Directors will be evaluating the Company's ability to continue operations. We have adequate resources to continue operations through June. In light of these clinical results, it may be difficult for us to raise additional resources. Our focus will be to maximize shareholder value by leveraging the Company's proprietary technology."
I'm not questioning EESO. I'm questioning your implication that WNBD has no sales.
"but she has sales"? Are you implying that WNBD does not have sales? You've got to be kidding... stick to the other board with that.